Overview

A Study of EDP-938 in Healthy Subjects

Status:
Completed

Trial end date:
2018-07-03

Target enrollment:

Participant gender:

Summary

This randomized, double-blind, placebo-controlled study will assess the safety, tolerability, and pharmacokinetics of single and multiple orally administered doses of EDP-938 in healthy adult subjects

Phase:

Phase 1

Details

Lead Sponsor:

Enanta Pharmaceuticals

Collaborator:

Pharmaceutical Research Associates